5.09
+0.07(+1.39%)
Currency In USD
| Previous Close | 5.02 |
| Open | 4.99 |
| Day High | 5.35 |
| Day Low | 4.99 |
| 52-Week High | 13.79 |
| 52-Week Low | 4.05 |
| Volume | 12,015 |
| Average Volume | 33,348 |
| Market Cap | 66.84M |
| PE | -0.9 |
| EPS | -5.66 |
| Moving Average 50 Days | 5.07 |
| Moving Average 200 Days | 5.61 |
| Change | 0.07 |
If you invested $1000 in INNOVATE Corp. (VATE) 10 years ago, it would be worth $0 as of December 25, 2025 at a share price of $5.09. Whereas If you bought $1000 worth of INNOVATE Corp. (VATE) shares 5 years ago, it would be worth $146.26 as of December 25, 2025 at a share price of $5.09.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
MediBeacon® Next Generation TGFR™ System Receives FDA Approval
GlobeNewswire Inc.
Dec 16, 2025 1:05 PM GMT
MediBeacon® TGFRTM System is a first-in-kind product for point of care kidney function assessmentCenters of Excellence commercialization in select academic medical centers begins in early 2026 NEW YORK, Dec. 16, 2025 (GLOBE NEWSWIRE) -- INNOVATE Co
INNOVATE Corp. to Report Third Quarter 2025 Results on November 12th
GlobeNewswire Inc.
Oct 22, 2025 8:05 PM GMT
NEW YORK, Oct. 22, 2025 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) announced today that it will release its financial results for the third quarter 2025 on Wednesday, November 12, 2025, after market close. The Com
MediBeacon receives regulatory approval to sell the Transdermal GFR System in China
GlobeNewswire Inc.
Oct 21, 2025 12:05 PM GMT
MediBeacon® Transdermal GFR System (TGFR) is a first-in-kind product for point of care assessment of kidney function in patients with normal or impaired renal functionThe TGFR will be available for sale in China before the end of the year NEW YORK, O